Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06323356
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-03-15
Brief Title:
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Sponsor:
Takeda
Organization:
Takeda
Study Overview
Official Title:
A Phase 3 Open-Label Multicenter Study to Evaluate the Efficacy Safety and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis GPP or Erythrodermic Psoriasis EP and side effect from the study treatment or TAK-279
All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules
Participants will be in the study for up to 61 weeks including 52 weeks of study treatment During the study participants will visit their study clinic for multiple times
All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules
Participants will be in the study for up to 61 weeks including 52 weeks of study treatment During the study participants will visit their study clinic for multiple times
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| jRCT2031230714 | REGISTRY | jRCT | None |